Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. is implementing a restricted stock incentive plan for 2024, aiming to attract and retain talent while aligning the interests of shareholders, the company, and employees [1][2]. Group 1: Incentive Plan Overview - The incentive plan involves granting 6.555 million restricted stocks, accounting for 1.58% of the company's total share capital of 415.6376 million shares [2][3]. - The grant price for the restricted stocks is set at 26.15 RMB per share [2][7]. - The plan will be effective for a maximum of 36 months from the date of stock grant [3][15]. Group 2: Eligibility and Conditions - A total of 325 employees, including directors, senior management, core technical personnel, and key business staff, are eligible for the incentive plan [3][12]. - The plan stipulates that the restricted stocks will not confer shareholder rights until they are vested, and they cannot be transferred or used as collateral before vesting [2][3]. - The vesting of stocks is contingent upon meeting both company-level performance targets and individual performance assessments [3][21]. Group 3: Performance Assessment - The performance assessment for the company will be based on revenue growth excluding impacts from public health events, with a baseline revenue of 2.709 billion RMB for 2023 [21][25]. - The performance targets for the first and second vesting periods will be evaluated based on the growth rates of revenue and sales of sequencing instruments [22][23]. - Individual performance will also be assessed, with ratings determining the actual number of shares vested [24][25]. Group 4: Management and Oversight - The plan will be managed by the board of directors, with a compensation and assessment committee responsible for drafting and revising the plan [10][11]. - The supervisory board will oversee the implementation of the plan, ensuring it aligns with the company's long-term development and does not harm shareholder interests [10][11]. - The plan requires approval from the shareholders' meeting before implementation [10][31]. Group 5: Adjustments and Accounting - Adjustments to the number of restricted stocks and their grant price may occur due to corporate actions such as stock splits or capital increases [29][30]. - The accounting treatment for the restricted stocks will follow relevant accounting standards, with costs recognized over the vesting period [30][31].